Advertisement - Members don't see this ad
https://www.usnews.com/news/best-st...it-was-cancer-it-wasnt-but-news-came-too-late
Interesting article.
Interesting article.
-
CycleTrack and SDN are teaming up to make medical school admissions more transparent and accessible! Read the announcement to learn how we’re supporting the future of CycleTrack’s free application-tracking tools .
Knownerror
Started by AZpath
Get help with your application
Use all the free resources available to you from SDN: articles, guides, expert advising, forums discussions, and school research.
Is this DNA/biopsy correlation thing becoming more commonly used out in the clinical world? Is this something big corporate labs offer/market or what?
Last edited:
It is not common.
It is not covered by Medicare. I am not sure if commercial insurance will pay for it.
No consensus yet that is all that helpful.
As the article points out the DNA correlation service did not prevent an error in this patient.
They did not go into why the process failed.
They also did not indicate that the pathology lab was the problem.
Reading between the lines, the error may have occurred at the clinic.
DNA correlation is no fail safe.
It is not covered by Medicare. I am not sure if commercial insurance will pay for it.
No consensus yet that is all that helpful.
As the article points out the DNA correlation service did not prevent an error in this patient.
They did not go into why the process failed.
They also did not indicate that the pathology lab was the problem.
Reading between the lines, the error may have occurred at the clinic.
DNA correlation is no fail safe.
Advertisement - Members don't see this ad
It is not a smart process to take a DNA swab at the same time as the biopsy because the error could more easily impact both samples.
Medicare will be forced to pay for it on prostate biopsies if that law goes through. I guess if your biopsy was from another body site, you won't get the same coverage.
Proposed bill targets prostate cancer misdiagnoses
DNA testing is being pushed by the in-office urology lab people. They see it as a revenue source. Just look at the history of Strand Diagnostics and who the founder is. Look at who made campaign contributions to the guy proposing this bill.
Proposed bill targets prostate cancer misdiagnoses
DNA testing is being pushed by the in-office urology lab people. They see it as a revenue source. Just look at the history of Strand Diagnostics and who the founder is. Look at who made campaign contributions to the guy proposing this bill.
This is, to me, essentially a glorified scam. Mislabeled specimens are a HUGE issue, but unlikely to be helped by this proposal. If a clinic has problems labeling its specimens appropriately, that's a huge problem for which an additional labeled specimen is not a solution. If there is a suspicion of mislabeled tissue, check it then.
